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1Epidemiological and observational studies have demon-strated that approximately half of the current heart failure 
(HF) burden is represented by patients who have preserved 
ejection fraction (HFpEF).1–3 The pathophysiologic basis 
that underpin the symptoms of HFpEF are complex, includ-
ing both central hemodynamic and peripheral vascular and 
muscular mechanisms.4,5 In particular, elevated left atrial 
(LA) pressure is considered a key driver of symptoms in HF,6 
and in HFpEF, this may be particularly evident during physi-
cal activity.7–10
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Background—Heart failure with preserved ejection fraction has a complex pathophysiology and remains a therapeutic 
challenge. Elevated left atrial pressure, particularly during exercise, is a key contributor to morbidity and mortality. 
Preliminary analyses have demonstrated that a novel interatrial septal shunt device that allows shunting to reduce the 
left atrial pressure provides clinical and hemodynamic benefit at 6 months. Given the chronicity of heart failure with 
preserved ejection fraction, evidence of longer-term benefit is required.
Methods and Results—Patients (n=64) with left ventricular ejection fraction ≥40%, New York Heart Association class 
II–IV, elevated pulmonary capillary wedge pressure (≥15 mm Hg at rest or ≥25 mm Hg during supine bicycle exercise) 
participated in the open-label study of the interatrial septal shunt device. One year after interatrial septal shunt device 
implantation, there were sustained improvements in New York Heart Association class (P<0.001), quality of life 
(Minnesota Living with Heart Failure score, P<0.001), and 6-minute walk distance (P<0.01). Echocardiography showed a 
small, stable reduction in left ventricular end-diastolic volume index (P<0.001), with a concomitant small stable increase 
in the right ventricular end-diastolic volume index (P<0.001). Invasive hemodynamic studies performed in a subset of 
patients demonstrated a sustained reduction in the workload corrected exercise pulmonary capillary wedge pressure 
(P<0.01). Survival at 1 year was 95%, and there was no evidence of device-related complications.
Conclusions—These results provide evidence of safety and sustained clinical benefit in heart failure with preserved ejection 
fraction patients 1 year after interatrial septal shunt device implantation. Randomized, blinded studies are underway to 
confirm these observations.
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The influence of a range of pharmacological approaches 
on morbidity and mortality in HFpEF has been examined in 
large randomized trials with the limited effect.11–14 Many of 
these agents were tested based on previous evidence of effi-
cacy in patients with HF with reduced ejection fraction. These 
include the use of renin–angiotensin–aldosterone antagonists 
to notionally reduce myocardial fibrosis and hypertrophy and 
β-blockers. The effectiveness of vasodilators including nitric 
oxide donors and cyclic GMP modulators has also been exam-
ined with variable effects.15–18
On the basis of the limited success of pharmacological 
management of HFpEF to date, an interatrial shunt device 
(IASD; Corvia Medical Inc., Tewksbury, MA) was developed 
to reduce the LA pressure in HFpEF. The REDUCE LAP-HF 
study (Reduce Elevated Left Atrial Pressure in Patients With 
Heart Failure) was designed to evaluate device performance 
and safety of the transcatheter, transvenous interatrial shunt 
device in symptomatic patients with HFpEF.19,20 Specifically, 
the device was engineered to reduce elevated LA pressure, par-
ticularly associated with exertion, while avoiding excessive left 
to right shunting.19,20 At 6 months, this approach was associated 
with improved functional and exercise capacity, with reduced 
exercise normalized pulmonary capillary wedge pressure, 
whereas modest increases in right heart cardiac output and right 
atrial pressure were observed.21 In this context, we sought to 
establish the longer-term effects of the interatrial shunt device. 
This report describes the clinical and echocardiographic out-
comes 1 year after IASD implantation, together with detailed 
rest and exercise hemodynamic data in a subset of patients.
Methods
The REDUCE LAP-HF study is a multicenter prospective, nonran-
domized, open-label, single-arm study designed to investigate the safe-
ty and performance of a novel transcatheter interatrial shunt device. 
The study design and primary results have been described in detail 
elsewhere.21,22 We report here the 1-year outcomes of the cohort of im-
planted patients (n=64), with particular regard to device performance, 
safety, and the durability of clinical and hemodynamic effects. All pa-
tients provided written informed consent, and the study was conducted 
with the approval of competent authorities and institutional ethics re-
view committees. Interpretation of the results and preparation of the 
article was the responsibility of the steering committee and principal 
investigators. The study was monitored by an independent Clinical 
Events Committee and Data Safety Monitoring Board. The sponsor 
played no role in the collection, analysis, or interpretation of the data.
Patient Population
We report here the 1-year outcomes of the cohort of patients who 
underwent successful IASD implantation, as described previously.21 
Briefly, HFpEF was defined as symptomatic HF (New York Heart 
Association class II-ambulant class IV), a left ventricular ejection 
fraction >40%, and an elevated pulmonary capillary wedge pressure 
(PCWP) at rest (>15 mm Hg) or during supine bicycle exercise (>25 
mm Hg) measured by right heart catheterization.22 Exclusion criteria 
included patients with moderate or greater right heart dysfunction and 
patients with significant valvular disease including >grade 2+mitral 
regurgitation, ≥grade 2+tricuspid regurgitation, ≥grade 2+aortic re-
gurgitation, or ≥moderate aortic stenosis (aortic valve area ≤1.1 cm2).
One-Year Follow-Up
Twelve months after device implantation, patients underwent clinical 
and echocardiographic assessment per protocol. Clinical parameters 
included 6-minute walk distance, New York Heart Association class, 
and quality of life evaluation using the Minnesota Living with Heart 
Failure questionnaire. Transthoracic echocardiography was per-
formed at the 12-month visit and as appropriate technically adequate 
images were analyzed at an independent core laboratory located at 
the University of Pennsylvania (PA). Parameters measured included 
left and right heart chamber sizes, tricuspid annular plane systolic 
excursion, and E/e′.
A subset of patients (n=18) underwent repeat right heart cath-
eterization at 12 months according to individual site capacity and pa-
tient willingness at 8 of 21 participating sites. Assessment of cardiac 
output and central hemodynamics (right atrial pressure, pulmonary 
artery pressure, and PCWP) was performed at rest and during supine 
bicycle exercise. The exercise protocol was as previously used, com-
prising symptom-limited supine bicycle exercise commenced at 20 
W with 20-W increments every 3 minutes until the patient achieved 
maximum effort. To account for the hemodynamic effect of differ-
ences in workload, we also calculated the workload corrected PCWP, 
as previously described.7 Blood samples were collected from the 
pulmonary artery and vena cavae at baseline and follow-up study to 
measure oxygen saturation and to evaluate left to right shunting as 
reflected by the Qp:Qs ratio. Hemodynamic records were analyzed by 
an independent core laboratory (PVLoops LLC, NY).
Statistical Methods
Normally distributed data are presented as mean±SD and non-normal 
data as median and 25th–75th percentile range. Between-groups and 
within-subject comparisons were performed using an unpaired or 
paired Student t test, respectively. Nonparametric tests were performed 
using a Mann–Whitney or signed-rank test as appropriate (for un-
paired or paired data). Repeated-measures ANOVA with post hoc test-
ing performed using Bonferroni testing for normally distributed data. 
Repeated-measures analysis of non-normal data was performed using 
Friedman test. Data provided for specific parameters represent only 
those cases in which measurements were available at all time points 
(baseline, 6 months, and 12 months). The null hypothesis was rejected 
at P<0.05. Statistical analysis was conducted using SPSS version 22.
Results
Clinical Outcomes, Quality of Life, and Functional 
Capacity
Of the 64 patients who underwent successful implantation 
all survived to 6 months as previously reported.21 During the 
period 6 months to 1 year, 3 patients died representing an 
overall 1-year survival of 95%. One patient died of combined 
pneumonia and renal failure, 1 patient had a fatal stroke (in 
an individual with CHA2DS2-VASc score of 6) and the cause 
of death in the third patient was undetermined (no previous 
adverse events had been reported). One patient did not return 
for the 12-month follow-up. There were a total of 17 HF hos-
pitalizations, occurring in 13 patients over the first year. Of 
these, 10 HF hospitalizations events occurred within the first 
6 months, in 10 patients. At 12 months, there were sustained 
significant improvements in New York Heart Association class 
and quality of life (Minnesota Living with Heart Failure) score 
as shown in Figure 1. Similarly, a sustained improvement in 
6-minute walk distance was observed at 12 months compared 
with baseline (363±93 versus 331±90 m; P=0.001; Figure 1; 
n=55), and the 12-month 6-minute walk distance was similar 
to that seen 6 months after device implantation.
Echocardiography
Color flow Doppler imaging confirmed the presence of 
ongoing left to right shunting at 12 months post device 
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implant, in all patients with adequate image quality and 
technique (n=48). At 12 months, left ventricular ejection 
fraction was unchanged, whereas right ventricular ejection 
fraction remained significantly elevated as observed at the 
6-month follow-up (Figure 2A and 2B). In conjunction, 
there were modest but stable reductions in the left ventric-
ular end-diastolic volume index with a concomitant rise in 
the right ventricular end-diastolic index (Figure 2C and 2D). 
By contrast, there were no progressive changes in the left or 
right atrial volume indexes between 6 and 12 months (Fig-
ure 2E and 2F). The E/e′ remained stable from baseline to 
6 and 12 months: 13.4±5.5, 13.1±7.6, and 12.2±4.2 (n=36), 
respectively. Of interest, although tricuspid annular plane 
systolic excursion was unchanged from baseline to 6 months 
(2.0±0.4 versus 2.0±0.4 cm), it was significantly increased 
at 12 months to 2.2±0.4 cm (P<0.05 versus baseline and 
6 months; n=36).
Invasive Hemodynamics and Exercise Testing
To further evaluate the longer-term influence of the IASD, 
rest and exercise right heart catheterization was conducted 
optionally in a subset (n=18) of patients at 12 months, thereby 
providing serial hemodynamic measures from baseline to 
6 and 12 months. Patients undergoing cardiac catheteriza-
tion at 12 months did not differ statistically from those who 
did not undergo catheterization with regard to demographic, 
clinical, or echocardiographic features (Table I in the Data 
Supplement). Within this cohort, exercise time increased sig-
nificantly from baseline to 6 months (8.2±3.4 versus 9.7±3.2 
minutes; P<0.05), and this increase was sustained at 12 
months (10.4±4.2 minutes; P<0.05 versus baseline). Simi-
larly, there was an increase in the supine cycling peak work 
capacity from baseline to 6 months (48±19 versus 60±16 
watts; P<0.01; n=17), and this increase was sustained at 12 
months (55±15 watts; P<0.01 versus baseline). The increase 
in supine exercise cycling peak workload was achieved with-
out an increase in PCWP.
Over the course of follow-up, there were no significant 
changes in resting or exercise systemic blood pressure (data 
not shown). As shown in the Table, there were no significant 
changes in the right atrial pressure, pulmonary artery pressure, 
or PCWP at rest or during exercise in the cohort of subjects 
who underwent cardiac catheterization at each time point. 
Implantation of the shunt device reduced the pressure gradient 
between the left and right atrium, as assessed by the PCWP 
to RA pressure gradient (Table), and this reduction was sus-
tained through to 12 months. As shown above, there was a sig-
nificant increase in the workload capacity, and this occurred 
in the absence of a change in the peak PCWP. In keeping with 
previous studies, we calculated the workload indexed PCWP.7 
As shown in Figure 3, IASD placement was associated with 
a sustained significant reduction in workload indexed PCWP 
>12 months. There was a significant increase in total right-
sided cardiac output after IASD implantation, as measured 
by thermodilution, and this continued through 12 months 
(Table). Left-sided cardiac output, measured by oximetry, was 
unchanged (Table). The Qp:Qs ratio in patients undergoing 
cardiac catheterization at 12 months was 1.25±0.25, which 
was unchanged from that at 6 months (1.27±0.24). Among 
the patients undergoing cardiac catheterization, assessment of 
the Qp:Qs confirmed the presence of continued left to right 
shunting in 6 patients in whom echocardiographic assessment 
was not possible. The pulmonary vascular resistance was also 
unchanged (data not shown).
Figure 1. A, Bar graph represents the effects of interatrial sep-
tal shunt device implantation on New York Heart Association 
(NYHA) class (n=60), (B) Minnesota Living with Heart Failure 
Score (MLWHF; n=60), and (C) 6-min walk distance (6MWD; 
n=55). **P<0.01, ***P<0.001 vs baseline. B and C, Data represent 
mean±SD.
Figure 2. Bar graphs representing (A) left ventricular ejection 
fraction (LVEF; n=53), (B) right ventricular ejection fraction (RVEF; 
n=47), (C) left ventricular end-diastolic volume index (LVEDVI; 
n=53), (D) right ventricular end-diastolic index (RVEDVI; n=48), 
(E) left atrial volume index (LAVI; n=53), and (F) right atrial volume 
index (RAVI; n=47). *P<0.05, **P<0.01, ***P<0.001 vs baseline. 
Data are mean±SD.
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Discussion
To directly alleviate the contribution of impaired diastolic 
function and the consequent exertion mediated rise in the 
LA pressure, the effect of an iatrogenic interatrial shunt has 
recently been studied by 2 groups including our own.21,23 
Computer modeling indicated that an 8-mm shunt opening 
could effectively reduce LA pressure in simulated HFpEF at 
rest and during exercise.19 The short-term, nonrandomized 
studies demonstrated significant positive effects on quality of 
life and functional capacity that were accompanied with mod-
est reductions in pulmonary capillary wedge pressure either at 
rest or during exertion.21,23
In the current report, we demonstrated the presence of 
sustained and meaningful clinical benefit as reflected by 
continued positive changes in quality of life score, 6-min-
ute walk distance, and New York Heart Association class. In 
conjunction, echocardiographic and oximetric studies con-
firmed the presence of ongoing IASD patency with evidence 
of left to right shunting and a reduction in the pressure dif-
ferential between left and right atrium, similar in degree to 
that observed at 6 months. At the 6-month time point, there 
was evidence of small but significant increases in right ven-
tricular end-diastolic volumes, but these remained stable at 12 
months. In parallel, there was a small, stable reduction in the 
left ventricular end-diastolic volume. Left and right atrial vol-
umes were not changed, and LV mass remained stable (data 
not shown). Serial echocardiographic parameters could not be 
assessed by the core laboratory in a minority of the subjects 
because of inadequate image quality, potentially limiting our 
ability to detect subtle changes in chamber volumes. Taken 
together, however, these data suggest that there was no evi-
dence of adverse remodeling after IASD placement, in keep-
ing with the small size of the shunt.
We also performed rest and exercise hemodynamic fol-
low-up in a limited cohort to address the potential concern that 
chronically increased right-sided blood flow could adversely 
affect pulmonary pressures and to investigate whether IASD 
placement continued to favorably affect LA pressure dynam-
ics. The PCWP to RA pressure gradient reduction was sus-
tained through to 12 months. The Qp:Qs ratio at 12 months 
was unchanged from that at 6 months. There was a sustained 
increase in right-sided cardiac output, with no change in rest-
ing left-sided cardiac output as measured by oximetry. The 
apparent absence of a reduction in left-sided cardiac output 
could potentially explained by volume retention although 
body weight was unchanged. The present data do not indi-
cate any evidence of increased pulmonary pressure or pul-
monary vascular resistance. Although there was no evidence 
of an effect of pulmonary capillary wedge pressure at rest or 
exercise, there was evidence of a sustained beneficial effect on 
bicycle exercise duration, workload, and on the workload cor-
rected wedge pressure. This latter parameter has been shown 
to be an important prognostic factor.24
Although the degree of functional impairment and 
impact on survival is similar across both HF with reduced 
ejection fraction and HFpEF, the pathophysiology of HFpEF 
differs in many ways from HF with reduced ejection frac-
tion. Patients are typically older and comorbidities includ-
ing atrial fibrillation, hypertension, obesity, frailty, chronic 
lung disease, and chronic kidney disease are all more fre-
quent. The underpinning myocardial biology is also prob-
ably more complex than in HF with reduced ejection fraction 
and likely more problematic in regard to the potential for 
reverse remodeling.25 Together, these factors may provide an 
explanation for the lack of a convincing long-term effects of 
pharmacological interventions to date in HFpEF patients.26 
Within this context, a safe and effective device-based ther-
apy provides a possible advantage. The maintained positive 
effect on clinical status and functional capacity coupled with 
evidence of sustained shunt patency and improved central 
hemodynamic also confirms the key role for elevated filling 
pressures as a driver of symptoms in HFpEF. Furthermore, 
by the nature of the mechanism of action of the shunt device, 
it would be unlikely that the results observed relate to an 
effect on the peripheral circulation.
The current study has some important limitations. First, 
the trial was a nonrandomized open-label study, and the key 
clinical outcome variables, while important for this patient 
population, were of a subjective or effort-dependent nature. 
As such, we cannot exclude the possibility of a placebo 
effect; however, it is of note that the early effects observed 
within the first 6 months were sustained to the same extent 
at the 12-month observation period. Second, although stroke 
Table.  Serial Hemodynamic Measurements
 Baseline 6 mo 12 mo
RAP rest, mm Hg 8±3 11±6 10±4
RAP exercise, mm Hg 17±6 20±9 21±8
PAm rest, mm Hg 25±8 23±7 26±8
PAm exercise, mm Hg 45±12 45±11 45±13
PCWP rest, mm Hg 19±6 16±8 17±6
PCWP exercise, mm Hg 36±9 33±9 33±10
PCWP-RAP gradient rest, mm Hg 10±5 6±2† 7±4‡
PCWP-RAP gradient  
exercise, mm Hg
20±7 14±4‡ 13±5*
Right-sided CO rest, L/min 5.2±1.3 6.3±1.4‡ 6.7±1.8*
Left-sided CO rest, L/min (n=10) 4.5±1.3 4.9±1.5 5.8±1.4
Right-sided CO exercise, L/min 8.9±2.3 10.3±2.2* 11.3±2.9‡
Data are mean±SD (n=18 patients). CO indicates cardiac output; PAm, mean 
pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; and 
RAP, right atrial pressure.
*P<0.05, †P<0.001, and ‡P<0.01 vs baseline.
Figure 3. Bar graph showing workload indexed peak exertion 
wedge pressure before and after interatrial shunt device place-
ment (n=16). *P<0.05, **P<0.01 vs baseline. Data are mean±SD. 
PCWP indicates pulmonary capillary wedge pressure.
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occurred in 1 individual at high preexisting risk for a cere-
brovascular event, it is not possible to definitively exclude a 
potential device-related event although it was not adjudicated 
as device-related by the Clinical Events Committee. Third, 
in some cases, information at each observation point was not 
available, potentially leading to bias; however, the number 
of complete within-subject data sets across time was mini-
mally reduced. Finally, only a subgroup of patients underwent 
hemodynamic assessment at 12 months, preventing reporting 
of longitudinal changes in the entire cohort.
Taken together, this study provides the longest experience 
with an interatrial shunt device specifically developed for 
the management HFpEF. The data provide additional longi-
tudinal support for the safety and efficacy of this approach. 
Randomized trials, with blinded patients and physician asses-
sors, are currently underway and are required to validate the 
utility of this novel therapy.27
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CLINICAL PERSPECTIVE
Approximately half of all patients with heart failure are found to have a preserved left ventricular ejection fraction. The 
pathophysiology of heart failure with preserved ejection fraction is complex, and treatment remains a major therapeutic 
challenge. Elevated left atrial pressure, particularly during exercise, is a fundamental contributor to morbidity and mortality. 
Based on this pathophysiologic mechanism, an interatrial shunt device was developed to decompress the left atrium as a 
therapy for heart failure with preserved ejection fraction. Preliminary studies illustrated the potential clinical and hemody-
namic benefit of this approach. The current open-label study in symptomatic patients with left ventricular ejection fraction 
>40% demonstrates the presence of sustained improvements in New York Heart Association class, quality of life, and 6-min-
ute walk distance, 1 year after device implant. Invasive hemodynamic studies performed in a subset of patients demonstrated 
a sustained reduction pulmonary capillary wedge pressure at a given workload. Randomized, blinded studies are underway 
to confirm these observations.
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SUPPLEMENTAL TABLE 1.  
 
Subject profile according to 12 month hemodynamic study 
 HD  Study   No-­HD  Study  
Age   69±8     69±9  
Baseline  BMI  (kg/m²)   31±6     33±6  
12  Months  BMI  (kg/m²)   31±6     31±5  
Baseline  NT-­Pro  BNP  (pg/mL)     551  (262-­909)     377  (156-­1098)  
12  Months  NT-­Pro  BNP  (pg/mL)     419  (224-­637)   509  (216-­1008)  
Baseline  6MWD  (m)     338±94     325±101  
12  Months  6MWD  (m)   376±86   352±98  
Baseline  MLHFQ  score     51±19     47±20  
12  Months  MLHFQ  score   29±21   36±21  
Baseline  NYHA  Class     2.8±0.4     2.6±0.5  
12  Months  NYHA  Class     2.0±0.6     1.9±0.7  
Baseline  LVEF  (%)   47±7     45±7  
12  Months  LVEF  (%)     48±7     46±5  
Baseline  RVEF  (%)   54±9   61±12  
12  Months  RVEF  (%)       62±9   66±13  
Baseline  LVEDVI  (mL/m2)     73±15     66±11  
12  Months  LVEDVI  (mL/m2)     63±15     58±14  
Baseline  PCWP  (mmHg)   19±6     17±5  
Baseline  CO  (L/min)  at  rest     5.3±1.2     5.6±1.7  
Data are mean±SD, except for NT-proBNP (median, 25th-75th percentile). 
Subject numbers: HD Study (n=18); No-HD Study (n=46 at baseline; n=42 at 12 months). 
